Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value

Candel Therapeutics, Inc. (CADL)
CADLNASDAQHealthcareBiotechnology
As of Nov 20, 2026 close
Candel Therapeutics has a $396.99M market cap as of the Nov 20, 2026 close. Valuation, profitability, balance sheet, dividend and growth figures below.
Market value, earnings multiples, and pricing ratios
Market capitalization, P/E ratios, and enterprise value
Valuation ratios based on stock price
EV-based valuation multiples
Current price, 52-week range, and moving averages
Outstanding shares, float, and per-share metrics
Wall Street analyst ratings and 12-month price targets (90 days)
Profit margins, return metrics, and earnings analysis
Profitability margins across income statement
ROE, ROA, ROIC, and capital efficiency ratios
Trailing twelve months revenue and earnings
Operating cash flow and free cash flow metrics
Year-over-year growth metrics
Balance sheet analysis, debt ratios, and dividend metrics
Total assets and cash positions
Liabilities, debt, equity, and working capital
Liquidity, leverage, and debt coverage ratios
Dividend yield, payout ratios, and growth metrics
Earnings, FCF, buyback, and shareholder yields
Risk assessment and quality metrics
Source: Market prices and company fundamentals from financial filings. Data as of Nov 20, 2026. Data sources and methodology
As of its most recent quarterly balance sheet, Candel Therapeutics (CADL) has $48.20M of total debt and $203.12M in cash and securities, a net cash position of $154.92M. Debt-to-equity is 0.37, the current ratio is 7.57 and the quick ratio is 7.57.
Compare these multiples with other companies in the Healthcare sector.